Loading...
Loading...
ACADIA Pharmaceuticals Inc.
ACAD, a biopharmaceutical company
focused on innovative treatments that address unmet medical needs in
neurological and related central nervous system disorders, today
announced that the U.S. Food and Drug Administration (FDA) has agreed
that the data from the pivotal Phase III -020 study, together with
supportive data from other studies with pimavanserin, are sufficient to
support the filing of a New Drug Application (NDA) for the treatment of
Parkinson's disease psychosis (PDP). As a result, ACADIA will no longer
conduct the Phase III -021 study that was planned as a confirmatory
trial and was scheduled to be initiated later this month.
ACADIA is currently focused on completing the remaining elements of its
See full press release© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in